Human protein tyrosine phosphatase inhibitors and methods of use

1. A compound having the formula:

wherein R is a unit chosen from:

i) hydrogen;

ii) substituted or unsubstituted phenyl; and

iii) substituted or unsubstituted heteroaryl ring;

Z is a substituted or unsubstituted [1,3,4]thiadiazol-2-yl unit having the formula:

R 1 is chosen from:

i) hydrogen;

ii) substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl;

iii) substituted or unsubstituted C 6 or C 10 aryl;

iv) —OR 4 ;

v) —C(O)OR 5 ;

vi) —COR 6 ;

vii) —NR 7 C(O)OR 8 ; and

viii) substituted or unsubstituted heteroaryl;

R 4 is hydrogen or substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl; R 5 is C 1 -C 6 linear or C 3 -C 6 branched alkyl, or benzyl; R 6 is C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl, or phenyl; R 7 is hydrogen or methyl; R 8 is C 1 -C 6 linear or C 3 -C 6 branched alkyl, or benzyl;

L is a unit having the formula —[C(R 9a R 9b )] y —;

R 9a and R 9b are each independently hydrogen, C 1 -C 6 linear or C 3 -C 6 branched alkyl, or phenyl; and

the index x is 0 or 1; the index y is from 1 to 4;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 , wherein the compound is a salt comprising anions chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, and citrate.

3. The compound according to claim 1 , wherein the compound is a salt comprising cations chosen from ammonium, sodium, lithium, potassium, calcium, magnesium, and bismuth.

4. The compound according to claim 1 , wherein R is phenyl.

5. The compound according to claim 1 , wherein R is a heteroaryl unit chosen from 1,2,3,4-tetrazol-1-yl, 1,2,3,4-tetrazol-5-yl, [1,2,3]triazol-4-yl, [1,2,3]triazol-5-yl, [1,2,4]triazol-4-yl, [1,2,4]triazol-5-yl, imidazol-2-yl, imidazol-4-yl, pyrrol-2-yl, pyrrol-3-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, [1,2,4]oxadiazol-3-yl, [1,2,4]oxadiazol-5-yl, [1,3,4]oxadiazol-2-yl, furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-3-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, [1,2,4]thiadiazol-3-yl, [1,2,4]thiadiazol-5-yl, and [1,3,4]thiadiazol-2-yl.

6. The compound according to claim 1 , wherein R is thiophen-2-yl or thiophen-3-yl.

7. The compound according to claim 1 , wherein R 1 is chosen from methyl, ethyl, n-propyl, iso-propyl, cyclopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, and cyclopropylmethyl.

8. The compound according to claim 1 , wherein L has the formula —CH 2 —.

9. The compound according to claim 8 , wherein R 1 is chosen from substituted or unsubstituted phenyl, naphthalen-1-yl, and thiazol-4-yl, said substitutions chosen from methyl, ethyl, n-propyl, hydroxy, hydroxymethyl, methoxy, fluoro, chloro, and trifluoromethyl.

10. A compound according to claim 9 , wherein R 1 is chosen from phenyl, naphthalen-1-yl, 3-methoxyphenyl, and 2-methylthiazol-4-yl.

11. A composition comprising:

A) one or more compounds according to claim 1 ; and

B) one or more excipients or carriers.